YYYuzheng Yan

Yuzheng Yan

*This is an algorithmically generated author record based on publicly available information.

Yuzheng Yan has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictive Value of Age-Adjusted Charlson Comorbidity Index on Survival Outcomes of Hepatocellular Carcinoma Patients with Comorbidities Undergoing Radiofrequency Ablation

    by Yuzheng Yan, Sijie Xiao, Feng Xia, Huaqiang Bi, Chunlin Tang, Kai Feng, Kuansheng Ma, Qiang Wang

    This study aimed to explore the predictive value of Age-Adjusted Charlson Comorbidity Index (ACCI) on survival outcomes in patients with hepatocellular carcinoma (HCC) and comorbidities undergoing radiofrequency ablation (RFA). This study is a retrospective, single-center study which included 158 patients with HCC newly diagnosed at our center from January 2015 to December 2021 who had comorbidities prior to RFA treatment. Patients were divided into two groups (≤4 and >4) according to the optimal cutoff value of ACCI determined by X-tile analysis based on overall survival (OS), and comprehensive clinical, laboratory, and tumor characteristic data were collected. The primary endpoints were OS and recurrence-free survival (RFS), analyzed using the Kaplan-Meier method and Cox proportional hazards model. Patients in the high ACCI group (>4) were independently associated with worse OS and RFS compared to those in the low ACCI group (≤4). Multivariate Cox analysis confirmed that ACCI >4 was an independent risk factor for both OS and RFS, with hazard ratios (HR) of 2.07 and 2.05, respectively. In addition to ACCI, other independent predictors for worse OS included tumor max-diameter (HR: 1.69, P < 0.001) and elevated level of preoperative α-fetoprotein (HR: 1.91, P = 0.007), while preoperative albumin (HR: 0.93, P=0.001) was a significant protective factor for OS. For RFS, significant risk factors included tumor max-diameter (HR: 1.79, P < 0.001) and prothrombin time ≥ 13 seconds (HR: 2.38, P = 0.001). ACCI may serve as a useful prognostic predictor for survival outcomes in HCC patients with comorbidities undergoing RFA.

  • Open Access

    Short- and Long-Term Outcomes of Radiofrequency Ablation for Early Hepatocellular Carcinoma with Liver Dysfunction

    by Sijie Xiao, Yuzheng Yan, Huaqiang Bi, Tengqian Tang, Kai Feng, Feng Xia, Chunlin Tang, Kuansheng Ma, Qiang Wang

    This study aimed to report the short- and long-term outcomes of radiofrequency ablation (RFA) for the treatment of patients with early hepatocellular carcinoma (HCC) with different levels of liver dysfunction. This retrospective study included early HCC patients with Child-Pugh score (CPS) ≥ 7 cirrhosis who underwent percutaneous RFA at our center. The short-term efficacy of RFA was evaluated based on postoperative technical success, effectiveness, and complications, and long-term efficacy was evaluated based on recurrence-free survival (RFS) and overall survival (OS). The impact of liver dysfunction on both outcomes was explored. In total, 176 patients (median age, 57 years; 149 males) were included. The technical success rate, technical effectiveness, and incidence of postoperative major complications were 96.6%, 97.7%, and 3.4%, respectively. There were no significant differences between the groups divided according to CPS. The 1-, 3-, and 5-year RFS rates were 54.1%, 28.8%, and 16.8%, respectively, no significant differences were observed between the groups divided by Child-Pugh score (p = 0.057), Albumin-Bilirubin grade (p = 0.170), or Model for End-stage Liver Disease score (p=0.210). The 1-, 3-, and 5-year OS rates were 91.3%, 67.1%, and 58.5%, respectively, and OS decreased as ALBI grade increased (p = 0.015). Multivariate Cox analysis demonstrated that male patient (hazard ratio, 2.31; p = 0.013) and recurrent HCC (hazard ratio, 2.347; p < 0.001) were independent predictive factors for RFS; hypertension (hazard ratio, 2.828; p = 0.042) and tumor number (hazard ratio, 2.445; p = 0.011) were independent predictive factors for OS, respectively. Radiofrequency ablation is safe and effective for early HCC patients with early hepatocellular carcinoma and liver dysfunction.